Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Acute Lymphoblastic Lymphoma

St. Jude Children's Research Hospitalprotein_peptidePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

83 Active assets in the Acute Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
ASPARAGINASE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 4BBB
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BBB
PEGASPARGASE
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 4BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →